Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Florbetapir F 18 - Avid Radiopharmaceuticals

Drug Profile

Florbetapir F 18 - Avid Radiopharmaceuticals

Alternative Names: 18F-AV-45; Amyloid imaging agent; Amyvid; AV-45; Florbetapir (18F); Florpiramine F 18

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pennsylvania
  • Developer Avid Radiopharmaceuticals; Chang Gung Memorial Hospital
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease
  • Phase II Cognition disorders
  • No development reported Parkinson's disease

Most Recent Events

  • 29 Nov 2022 Phase II development in Cognition disorders (Diagnosis, In adults, In the elderly) is ongoing in Taiwan (IV) (NCT04588649)
  • 16 May 2022 Avid Pharmaceuticals terminated a phase II trial in Alzhiemers disease in Netherlands (EudraCT2012-001599-12)
  • 27 Aug 2021 Invicro initiates a phase I trial to compare amyloid burden assessed by amyloid PET imaging in USA (NCT05164536)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top